Company · founded 2009
Chrysalis BioTherapeutics (United States)
Galveston, United States · chrysbio.com
- Citations, last 5 years
- 493
- Works, last 5 years
- 18
- h-index
- 26
- Scientists listed
- 1
- Grants since 2016
- 7
Grants received
2024–2025 · research · R41
Targeting a disease-specific conformation of fibronectin as a novel approach for liver fibrosis treatment
Jagathpala Shetty · Chrysalis BioTherapeutics (United States) · funded by National Institutes of Health
2024–2025 · research · R44
Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis
Ping Hu · Chrysalis BioTherapeutics (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis
Ping Hu · Chrysalis BioTherapeutics (United States) · funded by National Institutes of Health
2020–2021 · contract · N01
SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK
Laurie Sower · Chrysalis BioTherapeutics (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION
Laurie Sower · Chrysalis BioTherapeutics (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION
Laurie Sower · Chrysalis BioTherapeutics (United States) · funded by National Institutes of Health
2017–2018 · contract · N01
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION
Laurie Sower · Chrysalis BioTherapeutics (United States) · funded by National Institutes of Health